Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-444 vs REFRESH OPTIVE UD in Dry Eye Disease
NCT07284381Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ABBV-444 in dry eye disease (DED), sponsored by AbbVie Inc.. Started Dec 2025; status: completed.
02
Drugs
ABBV-444
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07284381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284381.